Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) received a $3.00 price objective from equities researchers at Maxim Group in a note issued to investors on Tuesday. The firm presently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price target would indicate a potential upside of 391.80% from the company’s current price.

Other equities analysts have also recently issued research reports about the stock. HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Actinium Pharmaceuticals in a research report on Monday, October 23rd. Roth Capital reiterated a “buy” rating and set a $6.00 price target on shares of Actinium Pharmaceuticals in a research report on Monday, October 23rd.

Actinium Pharmaceuticals (ATNM) opened at $0.61 on Tuesday. Actinium Pharmaceuticals has a 52-week low of $0.54 and a 52-week high of $1.72.

ILLEGAL ACTIVITY NOTICE: This news story was reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.watchlistnews.com/actinium-pharmaceuticals-inc-atnm-given-a-3-00-price-target-by-maxim-group-analysts/1704239.html.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).

Receive News & Ratings for Actinium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.